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Osteopontin (OPN), an adhesive, matricellular glycoprotein, is a rate-limiting factor in tumor promotion of skin
carcinogenesis. With a tumor promotion model, the JB6 Cl41.5a cell line, we have shown that suppressing 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced OPN expression markedly inhibits TPA-induced colony formation in soft
agar, an assay indicative of tumorigenic transformation. Further, the addition of exogenous OPN promotes colony
formation of these cells. These ﬁndings support a function of OPN in mediating TPA-induced neoplastic transformation of
JB6 cells. In regard to themechanism of action byOPN, we hypothesized that, for JB6 cells grown in soft-agar, secretedOPN
induced by TPA stimulates cell proliferation and/or prevents anoikis to facilitate TPA-induced colony formation. Analyses of
cell cycle and cyclin D1 expression, and direct cell counting of JB6 cells treated with OPN indicate that OPN does not
stimulate cell proliferation relative to non-treated controls. Instead, at 24 h, OPN decreases anoikis by 41%, as assessed by
annexin V assays. Further, in suspended cells OPN suppresses caspase-8 activation, which is mediated speciﬁcally through
its RGD-cell binding motif that transduces signals through integrin receptors. Transfection studies with wild-type and
mutant focal adhesion kinases (FAK) and Western blot analyses suggest that OPN suppression of caspase-8 activation is
mediated through phosphorylation of FAK at Tyr861. In summary, these studies indicate that induced OPN is a
microenvironment modulator that facilitates tumorigenic transformation of JB6 cells by inhibiting anoikis through its RGD-
dependent suppression of caspase-8 activity, which is mediated in part through the activation of FAK at Tyr861.
© 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Tumor promotion occurs when initiated cells,
possessing permanent genetic alterations, acquire
proliferative capacity and form benign tumors. This
stage is the first-rate limiting step in multistage
carcinogenesis, since initiated cells may die or remain
dormant, surviving in a favorable microenvironment
for an extended period prior to transformation. We
have shown that induced expression of amatricellular
protein, osteopontin (OPN) is an important microen-
vironment modulator in tumor promotion that
facilitates papilloma development, likely through
enhancing the survival of initiated basal keratino-
cytes [1].
OPN is a secreted, adhesive glycoprotein consisting
of three main conserved motifs: a consecutive
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sequence of 8–10 aspartic acid residues shown to bind
calcium or hydroxyapatite; an Arg-Gly-Asp (RGD)
sequence that binds integrins; and an Asp-Arg-Tyr-
Leu-Lys-Phe-Arg (DRYLKFR) sequence that interacts
with the hyaluronic acid receptor, CD44s, or it
variants. The primary structure of OPN reflects its
functions in mineralization, prevention of calcifica-
tion, chemotaxis, cell signaling, and cell survival [2–
4]. The expression of OPN is induced during patho-
logical conditions such as cancer, and it is thought to
facilitate tumorigenesis, cancer progression, and
metastasis [1,5–7]. In the present investigation, we
used the “initiated” transformation-sensitive (Pþ),
epidermal-like cells to elucidate the mechanism by
which induced OPN enhances tumorigenic
transformation.
The promotable murine JB6 Cl41.5a cell line (JB6),
established by Colburn et al. [8], has beenwidely used
as amodel for studies of tumor promotion. These cells
are stable in that, over several passages, they retain
their morphology and haveminimal capacity to form
colonies in soft agar. However, upon treatment with
the skin tumor promoter, 12-O-decanoylphorbol-13-
acetate (TPA), they become transformed, as assessed
by their capacity to form colonies on soft agar, a
property that correlates with tumorigenic transfor-
mation in vivo [9]. Studies using these promotable
cells have identified proto-oncogenes, AP-1 and
ornithine decarboxylase [10,11], and the tumor
suppressor Pdcd4 [12], which are predictive of
promoting or inhibiting tumor promotion in intact
animals [13–16].
We have shown that OPN is also a mediator of TPA-
induced transformation of JB6 cells [17]. These cells
normally express minimal levels of OPN, but TPA
markedly stimulates its mRNA, which was originally
named 2ar by Denhardt and colleagues [18]. A steady-
state level of OPNmRNA is induced by TPA as early as
2–4h, peaks at 16h, and decreases slightly by 24h.
This increase at the mRNA level correlates with the
increase in the level of secreted OPN [19,20].
Furthermore, if the media is not limiting, TPA-
induced expression of OPN can persist for at least
4 d. Because previous studies have shown that the
induction of colony formation requires the presence
of TPA for at least 4 d [21], the continuous presence of
secreted OPN suggests that OPN may function as an
autocrine factor mediating TPA-induced colony for-
mation in soft-agar. Indeed, TPA-treated JB6 cells
exhibit increase adhesion to plate-bound OPN (likely
through avb5 integrin) and concomitantly, decrease
adhesion to fibronectin (FN) and vitronectin (VN)
[22]. Furthermore, OPN stimulates colony formation
of JB6 cells and that suppression of OPN expression
compromises TPA-induced transformationof JB6 cells
[17].
Here, we determine mechanism(s) by which in-
duced OPN facilitates colony formation of JB6 cells.
Our data indicate that OPN does not stimulate
proliferation of JB6 cells, but rather enhances the
survival of cells suspended on agar, an assay used to
mimic early time points of soft-agar assays [23].
Furthermore, the capacity of OPN to delay anoikis of
JB6 cells by suppressing caspase-8 activity is mediated
through its RGD-cell binding motif and, in part, the
phosphorylation of focal adhesion kinase (FAK) at
Tyr861.
MATERIALS AND METHODS
Cell Line
Mouse JB6 Cl41.5a (JB6) cells, which are preneo-
plastic and epidermal-like, were generously provided
by Dr. N. Colburn of the National Cancer Institute,
Frederick, MD [24]. Cells were maintained in Eagles
Minimum Essential Medium (MEM) supplemented
with 5% heat-inactivated fetal bovine serum (HI-FBS)
(Hyclone, Logan, UT), 4mM glutamine (Irvine Scien-
tific, Santa Ana, CA), 50units/ml of penicillin, 50mg/
ml of streptomycin, and 0.125mg/ml of amphotericin
B (Irvine Scientific). To avoid mycoplasma contami-
nation, cells were sub-cultured prior to confluence
and checked monthly by use of DNA fluorochrome
staining [25]. Cell numbers were determined by use of
a hemocytometer.
DNA Analyses by Flow Cytometry and Cell Proliferation
Analyses
JB6 cells were seeded at equal density (25,000 cells/
cm2) in 60-mmdishes and after 24h, treated with PBS
and/or 3mg/ml of recombinant rat OPN (rOPN), or
0.001% dimethylsulfoxide (DMSO), and/or 10ng/ml
(16.2nM) of TPA (duplicate or triplicate dishes/
treatment) with no media change. rOPN was purified
as previously described [26]. Only purified batches
with low endotoxin (< 1ng in 45mg of rOPN) were
used. Cells were harvested at 25h after treatment and
fixed with 100% ethanol. DNA analyses were per-
formed according to a modified protocol [27]. Fixed
suspended cells were treatedwith 200mg/ml of RNase,
stained with 20mg/ml of propidium iodide (Sigma, St
Louis, MO), and incubated for 30min prior to flow
cytometry analyses (Becton Dickenson FACS Calibur,
BD Biosciences, San Jose, CA). DNA contents in
various stages of cell cycle were determined by
ModFitLT V3.3.11 (Mac).
For cell proliferation analyses, similar experiments
were performed, except that cells were seeded in 24
wells (triplicatewells per treatment) and incubated for
48h with rOPN or PBS as control in the presence of
growth media. Cells were trypsinized and counted by
use of a hemocytometer.
Over-Agar Assay
JB6 cells were trypsinized and suspended with or
without drugs (see below for further details) in MEM
containing 5% HI-FBS on 0.7% agar. Cells were then
harvested at various time points for determination of
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secreted OPN by enzyme-linked immunosorbant
assay (ELISA), annexin V and caspase activity, and
for Western blot analyses. All over-agar assays were
performed in the presence of 5% HI-FBS, unless
otherwise stated.
ELISA for Secreted OPN
For analyses of secreted OPN from adherent JB6
cells, cells were seeded at equal density in 24-well
culture dish. After 24h, cells were not treated or
treated with 10ng/ml of TPA or 0.001% DMSO
(control). Likewise, suspended cells in over-agar in
24-well cultured dishes were treated as described
above. Conditioned media after 24h of treatment
were collected and analyzed for secreted OPN with
ELISA (Assay Design, Ann Arbor, MI). The number of
cells of each treatment was determined with a
hemocytometer. The secreted OPN concentration
was normalized to 10,000 cells.
Anoikis Analyses by Annexin V Labeling
Cells were seeded at 9,000 cells/cm2 in 15025-
mm tissue culture plates. After 2 d, cells were trypsi-
nized and re-suspended in 10ml of media with PBS
and/or 4mg/ml of rOPN, or 0.001% of DMSO and/or
10ng/ml of TPA and layered on 0.7% agar-coated
15025-mm dishes. After 24h, cells were harvested,
rinsed with PBS, and re-suspended in 500ml of
binding buffer from an Annexin V-FITC Apoptosis
Detection Kit (BD PharmingenTM, San Jose, CA). Re-
suspended cells from each sample were placed in four
tubes containing 100ml per tube. Cells in each of the
tubes were either labeled or not labeled with Annexin
V-FITC or propidium iodide, or both, and analyzed by
flow cytometry. The experiment was repeated two
more times.
Caspase Activity Assay With RGD-Cell Binding or CD44-
Binding Peptides, Wortmannin, or FAK Inhibitor 14
To screen for the various caspases activated upon
anoikis of JB6 cells, the ApoAlert Caspase Profiling
Plate was used according to manufacturer’s instruc-
tions (Clontech, Mountain View, CA). Briefly, cells
(2106) layered on agar were treated with or without
rOPN for designated times prior to harvest. Pelleted
cells were lysed in lysis buffer (0.1M Hepes, pH 7.4,
containing 2mMdithiothrietol, and0.1%Chaps) and
incubated with 50ml of 50mM fluorogenic caspase-8
peptide substrate, Ac-IETD-AFC (7-amino-4-trifluor-
omethylcoumarin) for 2h at 378C. Protein concen-
tration was determined by bicinchoninic acid
method. The release of AFC was measured with
excitation at 400nm and emission at 505nm using
a fluorescence spectrophotometer. For analyses of
caspase-9 and caspase-3 activities, similar experi-
ments were performed using substrates Ac-LEHD-
AMC (7-amino-4-methoxy coumarin) and Ac-DEVD-
AFC, respectively. In assessing caspase-3 activity, an
inhibitor to caspase-3 activity (10mM) was also
included. Data are presented as fold-increase of
caspase activity relative to that of 0-h time point.
Subsequent analyses on the effects of rOPN in
suppressing caspase-8 activity of suspended JB6 cells
were performed using the caspase-8 substrate, Ac-
LETD-AFC (Bachem, Torrance, CA). For studies
involving wortmannin (Sigma) and FAK inhibitor
14 (Santa Cruz Biotechnology, Santa Cruz, CA),
adherent JB6 cells were pre-incubated with drugs for
30min and 1h, respectively, prior to suspension for
FAK and/or caspase-8 analyses. For studies involving
RGD-cell binding (GRGDSL) or CD44-binding (DRY-
LKFRI) peptides (American Peptide Company, Sun-
nyvale, CA), suspended cells are incubated with
peptides (GRGDSL, GRGESL or DRYLKFRI) with or
without rOPN for 1h prior to harvest. Experiments
were repeated at least two more times.
Immunoprecipitation and Western Blot Analyses
The suspended cells were collected after incubation
at the times as the indicated. The pelleted cells were
lysed by the RIPA buffer containing protease inhib-
itors (Roche, Indianapolis, IN) and sodium orthova-
nadate, a phosphatase inhibitor (Sigma). After
centrifugation of the preparations, the protein con-
tents in the supernatants were quantified by the
bicinconinic acid method (Thermo Fisher Scientific
Inc, Waltham, MA), and equal amounts of protein
were incubated with the polyclonal anti-FAK
(Santa Cruz Biotechnology) and Dynabeads Protein
A (Invitrogen, Grand Island, NY) at 48C overnight.
After incubation, cells lysates were centrifuged and
washed. The pellets were collected and subjected to
7% SDS–polyacrylamide gel electrophoresis. For
Western blot analyses, the proteins on the gel were
transferred onto PVDF membranes and probed with
antibodies to phospho-Tyr397 of FAK, FAK (Santa Cruz
Biotechnology) and phospho-Tyr861 or phospho-
Tyr925 of FAK (GenScript, Piscataway, NJ). Primary
antibody-binding sites were detected using secondary
antibody coupled to horse-radish peroxidase. Bands
were visualized by chemiluminescence (Luminata
Forte, EMD Millipore, Billerica, MA) using Blue-X
ray films. For cyclin D1 analyses, adherent cells were
treated with rOPN (3mg/ml) or PBS for 42h and cell
lysates were harvested forWestern blot analyses using
cyclin D1 antibody (Santa Cruz Biotechnology).
Cell Transfection With Mammalian Expression Vectors of
Wild-Type and Mutant FAK
JB6 cells were seeded and transfected at approxi-
mately 70% confluence with the plasmids at the
indicated times using LipofectamineTM (Invitrogen)
according to the manufacture’s instructions. The
medium was changed after 5h of incubation. The
plasmids transfectedwerewild-type FAK in pKH3 [28],
mutant FAK-Y861F (Tyr861 changed to Phe861) in pRC/
CMV [29], mutant FAK-Y925F (Tyr925 changed to
Phe925) in pcDNA3 [30], and vector only. To verify the
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expression of WT-FAK and mutant FAKs Western blot
analyses were performed.
Statistical Analyses
Data were expressed as mean standard deviation
(SD). t-Test was used for comparison between groups.
P values <0.05 were statistically significant. All the
analyses were performed using the Statistical Analysis
Program in SigmaPlot 11.0 or in Microsoft Office
Excel 2007.
RESULTS
We have previously reported that OPN mediates
TPA-induced tumorigenic transformation or colony
formation of JB6 cells [17] and addition of exogenous
OPN promotes colony formation of these cells. Here,
we addressed whether the OPN-enhanced colony
formation of these cells is accomplished by stimula-
tion of cell proliferation or by enhancement of cell
survival. Further, the molecular mechanisms in-
volved were determined. Adherent JB6 cells express
and secrete minimal levels of OPN [17]; only upon
treatment with TPA do they markedly express OPN.
To avoid the confoundingmitogenic andother effects
of TPA on JB6 cells, assays were performed with
addition of exogenous rOPN.
OPN Does Not Stimulate Proliferation of JB6 Cells
To determine whether OPN stimulates cell prolifer-
ation, cell cycle analyses, direct cell counting and
cyclin D1 expression were performed on cells at-
tached to culture dishes in the presence of soluble
rOPN. For cell cycle analyses, cells were treated for
25hwith 3mg/ml of rOPN, 10ng/ml of TPA as positive
control, or their corresponding negative controls, PBS
and 0.001% of DMSO, respectively. DNA contents at
different phases of cell cycle were measured by flow
cytometry. rOPN did not stimulate an increase in the
S-phase of the cell cycle and nor were any differences
inG0/G1 andG2/Mcell cycle phases observed relative
to PBS-treated control cells (Figure 1A, left panel, see
actual flow cytometry data, S1, S1-continued). In
contrast, TPA-treated cells showed an increase inDNA
content in the S-phase and a decrease in numbers of
cells in the G0/G1 and G2/M phases of the cell cycle
(Figure 1A, right panel, see actual flow cytometry
data, S2).
Further analyses of whether OPN stimulates cell
proliferation, performedby direct cell countingwith a
hemocytometer, also indicated that JB6 cells treated
with soluble rOPN for 48h did not increase in
numbers relative to control cells (Figure 1B). In
contrast to OPN, TPA stimulates proliferation of JB6
cells by 48h [31]. Further, Western blot analyses
showed that rOPN did not cause an increase in cyclin
D1 expression (data not shown). Collectively, these
findings indicate that soluble rOPN does not stimu-
late cell proliferation of JB6 cells.
OPN Prevents Anoikis of JB6 Cells
To determine if OPN prevents anoikis of JB6 cells
in soft agar, we used the over-agar assay, which
correlates with tumorigenic transformation in vi-
tro [23]. In this assay, cells were suspended in the
presence of serum to mimic the condition of soft-
agar assay and on 0.7% agar to allow for the recovery
of cells for biochemical analyses. Suspended cells
were treated with 4mg/ml of rOPN or PBS for 24 h
and analyzed for cell surface expression of phos-
phatidylserine (PS), an early marker for apoptosis.
Cells were incubated with annexin V, which binds
to PS, to detect early-stage apoptotic cells, propi-
dium iodide to detect dead cells, or both annexin V
with PI propidium iodide to detect necrotic or late-
stage apoptotic cells; flow cytometry was used for
analysis. After 24 h, rOPN suppressed by 41%
(annexin V binding only) the number of cells
undergoing anoikis relative to those treated with
PBS (Table 1).
In our analyses of cells in suspension, one may
argue that the overall percentage of apoptotic cells in
suspended JB6 cells is too low as compared to other
published studies. We attribute this to two main
reasons. Firstly, the methodologies of analysis for
apoptotic cells may differ, such as the application of
Hoechst 33528 nuclear staining versus the
annexin V assay. Hoechst 33528 staining scores
most of the late-stage apoptotic cells, which are
usually much higher [32], while the annexin V assay
separates the early-stage apoptotic cells (annexin V
only) from that of the late-stage apoptotic/necrotic
cells (annexin VþPI). In Table 1, the higher
percentages of late-stage apoptotic/necrotic cells of
JB6 cells suspended for 24h in PBS and OPN likely
correspond to those cells stained with Hoechst
33528. Secondly, the presence or lack of serum can
dictate the number of apoptotic cells in suspension.
In the present study, cells were suspended in 5% HI-
FBS resulting in lower percent of early-stage apopto-
tic cells (Table 1) as compared to studies where cells
were pre-incubated for 24 or 48h in serum-free
conditions [33]. Therefore, the components in the
serum can promote the survival of suspended cells.
Despite the presence of serum, we observed that the
addition of rOPN can further prevent anoikis of
suspended JB6 cells when compared to those treated
with PBS only (Table 1).
Suspended JB6 Cells Secrete Minimal Amounts of OPN
To determine if the prevention of anoikis by OPN is
only from the exogenous rOPN and not from
endogenous synthesis of OPN while cells are in
suspension, level of secreted OPN in conditioned
media at 24h was measured for suspended JB6 cells
not treated or treatedwith TPA as a positive control or
DMSO as vehicle control. Suspended cells secreted
minimal levels of OPN; only in the presence of TPA
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were substantial amounts (13-fold) of OPN present
(Table 2). Thus, the observed prevention of anoikis by
exogenous OPN (Table 1) is not confounded by the
minimal synthesis of endogenous OPNwhen cells are
in suspension.
Anoikis of JB6 Cells Is Mediated Through Caspase-8, -9,
and -3
To determine the mechanisms by which OPN
delays anoikis, activities of the various caspases
involved in the anoikis of JB6 cells were first evaluated
Table 1. Annexin V Analysis by Flow Cytometry of Suspended JB6 Cells Treated With OPN for 24 h
Treatment PBS-Susp OPN-Susp No tx-Ad
Viable cells (%), No staining for Annexin Vþ PI 62.35 6.50 70.85 6.40 90.56 3.36
Early-stage Apoptotic cells (%), Annexin V only 5.89 0.73 3.50 0.21 1.18 0.38
Late-stage apoptotic/necrotic cells (%), Annexin Vþ PI 20.80 0.03 16.87 2.50 6.83 3.70
Dead cells (%), PI only 10.97 7.2 8.76 4.00 1.43 0.83
Susp, suspended cells; No Tx, no treatment; Ad, adherent cells; PI, propidium iodide.
N¼3 per group.
P<0.05.
Figure 1. OPN does not stimulate cell proliferation of JB6 Cl41.5a cells. (A) Cell cycle analyses of JB6 cells treated
with OPN or TPA. Cells in growth media were treated with 3 mg/ml of rOPN (n¼ 8) and/or PBS (n¼ 6) or with 10 ng/
ml of TPA (n¼ 5) and/or 0.0001%DMSO (n¼ 5) for 25 h prior to analyses by ﬂow cytometry. See supplemental data,
Figures S1, S1-continued, and S2. (B) Cell proliferation analyses of JB6 cells treated with rOPN. Soluble rOPN (1.4mg/
ml) or 1% BSA as control were added to adherent JB6 cells for 48 h. Cells were collected by trypsinization and
counted by use of a hemocytometer, n¼ 3/treatment. Comparisons between groups were analyzed by t-test in this
ﬁgure and the rest of the other ﬁgures.
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with ApoAlert Caspase Profiling Plate. JB6 cells in
suspension triggered the activation of caspases-8, -9
and -3, which peaked as early as 1, 3, and 18h,
respectively (Figure 2A–C), but not caspase-2 (data not
shown). For caspase-8 additional studies were per-
formed to assess its activity with specific peptide
substrate not using the ApoAlert Caspase Profiling
Plate. These findings indicate that anoikis of JB6 cells
initiates a cascade of caspase activation, with caspase-
8 being the first to be activated, followed by caspases-9
and -3.
Suppression of Caspase-8 Activity/Anoikis of JB6 Cells by
OPN Is Not Dose-Dependent
To determine if anoikis suppressed by OPN is dose-
dependent, suspended cells were incubated with
increasing concentrations of rOPN, and caspase-8
activation was assessed. rOPN suppression of caspase-
8 activity was not dose-dependent. rOPN at low dose
(0.4mg/ml) did not suppress caspase-8 activity relative
to that of control cells. Instead a significant suppres-
sion of caspase-8 activity relative to that if control
cells was observed at 1.4mg/ml of OPN; while, no
further increase in suppression of caspase-8 activity
was observed at higher OPN concentration, 5mg/ml
(Figure 2D). These findings indicate that for JB6 cells
in suspension, there is a threshold amount of
exogenous OPN required to initiate the suppression
of caspase-8 activity and/or anoikis and that its effect
is receptor mediated.
In previous experiments (Figure 1 and Table 1),
which involved longer incubation times (24–48h),
higher concentrations of OPN (3–4mg/ml) were used,
because they were based on the concentration used in
the previous soft-agar assays [17]. Since higher
concentration of OPN beyond 1.4mg/ml did not
further suppress caspase-8 activity in over-agar assays,
subsequent experiments were performed at this
concentration.
Suppression of Caspase-8 Activity of JB6 Cells by OPN Is
Mediated Through Its RGD Motif
To establish if suppression of caspase-8 activation
by OPN is mediated through its integrin-binding
(RGD) or its putative CD44-binding (DRYLKFRI)
motif, cells in suspension were incubated with 1mM
of GRGDSL, GRGESL (a nonspecific peptide), or
DRYLKFRI with or without rOPN (1.4mg/ml). To
ensure competitive binding of these peptides with the
cell surface receptors, the amounts of the peptides
present (7.0nmol) were greater than that of OPN
(0.27nmol). Incubation of suspended JB6 cells with
the GRGDSL peptide for 1h suppressed caspase-8
activity as effectively as for cells treated with only
rOPN, relative to values for control cells (CT) with 1%
bovine serum albumin (BSA) (Figure 2E). The addition
of rOPN to cells with the GRGDSL peptide did not
further suppress caspase-8 activation relative to values
for cells incubated with GRGDSL only. In contrast to
the GRGDSL peptide, the non-specific GRGESL
peptide did not suppress caspase-8 activity relative
to that for untreated control cells; instead, only in the
presence of rOPN was caspase-8 activity suppressed.
Thus, rOPN suppression of caspase-8 activation is
mediated in part through its RGD motif.
Further, rOPN suppression of caspase-8 activation is
notmediated through theCD44 receptor, because the
DRYLKFRI peptide did not suppress caspase-8 activity
relative to untreated cells. Nevertheless, rOPN sup-
pressed this activity relative to that in cells exposed to
the DRYLKFRI peptide (Figure 2E).
OPN Suppression of Caspase-8 Activity Is Not Mediated by
the Activation of Phosphatidylinositol 3-Kinase (PI-3
Kinase)
Since OPN-enhanced survival of adherent cells can
bemediated by the phosphatidylinositol 3-kinase (PI-
3 kinase)/Akt signaling pathway through interaction
with the CD44 receptor [34], this possibility was
investigated for suspended JB6 cells. Adherent JB6
cells were pre-treated with the PI-3 kinase inhibitor,
wortmannin, at 0, 25, and 50nM for 30min prior to
placing the cells in suspension in the presence of
wortmannin, rOPN, or BSA. Inhibition of PI-3 kinase
by wortmannin increased the activity of caspase-8 of
suspended cells in a dose-dependent manner
(Figure 3A). However, addition of rOPN suppressed
the activity of caspase-8 in cells treated with 50nM of
wortmannin, suggesting that this suppression is
independent of PI-3 kinase activity.
OPN Suppression of Caspase-8 Activity Is Mediated
Through FAK Activation
FAK is a non-receptor tyrosine kinase protein
involved in development and processes such as cell
adhesion, migration, and survival [35]. Prolonging
cell survival through the binding ofmatrix proteins to
integrin receptors is mediated through the activation
Table 2. ELISA of Secreted OPN Protein in Adherent and Suspended JB6 Cells
Treatment None DMSO TPA
Adherent cells 0.6650.31 1.11 0.61 207.915.2
Suspended cells 0.6080.12 0.50 0.13 8.21.59
All samples, n¼3, except for adherent cells in DMSO, n¼2.
ng/10,000 cells standard deviation.
P¼0.001 relative to no treatment and DMSO-treated suspended cells.
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Figure 2. Anoikis of JB6 cells activates caspase-8, -9 and -3, which is
suppressed by rOPN, mediated through its RGD-cell binding domain
to inhibit caspase-8 activity. (A) JB6 cells suspended in agar were
analyzed for caspase-8 using the addition of its substrate after 0, 1, 3,
8, and 15 h of incubation, n¼ 3 to 8/time point. (B) Caspase-9 activity
analyzed using the ApoAlert Caspase Proﬁling Plate on cells treated as
in A, n¼ 3/time point. (C) Caspase-3 activity was analyzed using the
ApoAlert Caspase Proﬁling Plate with or without its inhibitor (10mM)
in cells suspended on agar at 0, 9, 18, and 24 h, n¼ 2. Caspase
activities are relative to that of 0 h in suspension. (D) Caspase-8
activities were analyzed after cells were suspended for 1 h in the
presence of 1% BSA (CT), 0.4, 1.4, or 5mg/ml of rOPN. Caspase-8
activities are relative to that at 0 h, n¼ 3/treatment. Histogram is
representative of 2 repeated experiments. (E) Caspase-8 activities
were determined in suspended cells incubated with 1.4mg/ml of
rOPN, or 1% BSAwith or without 1mMof RGD, 1mMof RGE, or 1mM
of D peptide for 1 h. RGD: GRGDSL peptide. RGE: GRGESL peptide. D:
DRYLKFRI peptide. Cells treated with 1% BSA only (CT) served as the
negative control. Caspase-8 activities are relative to that at 0 h
(n¼ 45/treatment).
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of FAK [36]. The possibility that FAK mediates OPN
suppression of anoikis or caspase-8 activation in JB6
cells was explored. Specifically, we investigated
whether OPN activates FAK to autophosphorylate at
tyrosine 397 (Tyr397), and whether FAK inhibitor 14,
which inhibits the autophosphorylation of FAK at
Tyr397, prevents OPN suppression of caspase-8
activity.
To determine if OPN stimulates FAK activation or
the autophosphorylation of FAK at Tyr397, suspended
Figure 3. OPN suppression of caspase-8 activity is mediated through
activation of FAK instead of PI-3 kinase. (A) PI-3 kinase does not
mediate OPN suppression of caspase-8 activity. Suspended JB6 cells
were treated with 0, 25, and 50 nM of wortmannin in the presence of
1% BSA or 1.4mg/ml of rOPN. Caspase-8 activities are relative to
suspended cells at 0 h. (B) Western blot analyses of FAK phosphoryla-
tion at Tyr397 of suspended cells in the presence of BSA (B) or rOPN (O)
for 0, 5, and 15min in 5% HI-FBS. Cell lysates (450mg) were
immunoprecipitated with antibody to total FAK and probed with anti-
FAK phosphorylated-Tyr397 (P-Tyr397) (ﬁlm exposure time was 10min),
followed by anti-total FAK antibody (ﬁlm exposure time 5–8 s). (C)
Western blot analyses of FAK phosphorylation at Tyr397 of suspended
cells in serum-free medium. Prior to suspending cells in serum-free
medium containing only 1% BSA, they were rinsed with PBS after
trypsinization. Cell lysates (800mg) were immunoprecipitated with
antibody to total FAK and probed with anti-FAK phosphorylated-
Tyr397 (P-Tyr397). Film exposure times were 10min for top panel and
5–8 s for lower panel. (D) Western blot analyses of FAK phosphoryla-
tion at Tyr397 of suspended cells in serum containing medium treated
with FAK inhibitor 14. Cell lysates (800mg) were treated as described in
(B). For blots probed with anti-P-Tyr397, ﬁlm exposure time is  5 s and
for blots probed with total anti-FAK, ﬁlm exposure time is 10min. (E)
Caspase-8 activity was analyzed after the suspending cells were
incubated with 1mM of FAK inhibitor 14 in the presence of 1% BSA or
1.4mg/ml of rOPN for 1 h, n¼ 3/treatment. Caspase-8 activity of cells
treated with OPN was normalized to that of cells treated with 1% BSA.
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cells in the presence of serum were treated with 1%
BSA or rOPN and harvested after 0, 5, and 15min of
suspension. Cells at 0 time point, immediately after
trypsinization, showed no activation of FAK. Howev-
er, after 5 and 15min of suspending cells on agar we
observed FAK autophosphorylation at Tyr397 and
the addition of rOPN did not further increase the
level of FAK activation compared to BSA-treated cells
(Figure 3B). This data suggest two possibilities, (1)
suspending cells on agar activates FAK to autophos-
phorylate, or (2) serum in the medium activates FAK.
To address these possibilities, we repeated the over-
agar assay in serum-free medium with only 1% BSA.
Without serum, cells suspended in BSA showed
minimal or no FAK activation at 0 time point or after
5min, but an increase of FAK activation at 15min,
which could be due to residual serum resulting in
minimal activation of FAK. FAK activation is likely
not due to the physical suspension of cells, because if
it is, then we should observe FAK activation by 5min
in BSA only medium. In contrast to BSA-treated cells,
rOPN stimulated FAK activation by 5min of cell
suspension,which persisted at 15min, Figure 3C. This
indicates that when cells are suspended without
serum, OPN is required to stimulate the autophos-
phorylationof FAK at Tyr397. In the presence of serum,
cells are likely interacting with existing integrin
bindingmatrix proteins such as FN andVN consisting
of RGD-cell binding motifs [37], and consequently,
FAK activation was observed by 5min in the presence
of BSA only (Figure 3B), but with the addition of
rOPN, the FAK activation persists since there are three
potential integrin-binding proteins available. Our
conclusion is further supported by previous studies
indicating that in serum-free condition, suspended
mouse keratinocytes and SP1 cells showed no activa-
tion or autophosphorylation of FAK [38,39]. Instead,
the addition of FN-coated beads to suspended SP1
cells stimulated autophosphorylation of FAK at Tyr397
and Tyr577 [39].
To determine whether inhibiting autophosphory-
lation of FAK at Tyr397 using FAK inhibitor 14 prevents
the OPN suppression of caspase-8 activity, we first
evaluated the effect of this inhibitor in suppressing
the phosphorylation of FAK at Tyr397 in suspended
JB6 cells in the presence of serum. Adherent cells pre-
treatedwith FAK inhibitor 14 for 1h at concentrations
of 1 or 10mM followed by cell suspension for 5min
resulted in suppressed autophosphorylation of FAK at
Tyr397 (Figure 3D). These doses of FAK inhibitor 14
used also showed similar effects in a breast cancer
cell line [40]. However, unlike cancer cells, we also
observed that by 1h treatment with 10 and 100mMof
the FAK inhibitor, the viability of adherent JB6 cells
were significantly reduced compared to those cells
treated with control and 1mM (data not shown).
Therefore, only 1mM of FAK14 inhibitor was used in
the presence of rOPN for suspended JB6 cells to
determine if it prevents OPN suppression of caspase-8
activation. The results showed that, by preventing the
autophosphorylation of FAK at Tyr397, rOPN was not
able to suppress caspase-8 activity (Figure 3E). There-
fore, FAK activation is necessary and mediates OPN
suppression of anoikis, likely through phosphoryla-
tion of alternative site(s) of FAK, since cells suspended
in serum with BSA already induced autophosphor-
ylation of FAK at Tyr397 (Figure 3B).
OPN Stimulates the Phosphorylation of FAK at Tyr861 in
Suspended JB6 Cells
Besides the autophosphorylation of FAK at Tyr397-
additional FAK phosphorylations at Tyr861 have
been implicated to be required for mediating cell
survival of adherent endothelial cells in response to
vascular endothelial growth factor and cancer cells in
response to hyperosmotic stress [33,41]. Here, we
determined if, for suspended JB6 cells, OPN stimulates
the phosphorylation of FAK at Tyr861. Immunopre-
cipitation with anti-FAK antibody followed by West-
ern blot analyses using antibody specific for FAK
phospho-Tyr861 showed that, in cells suspended for 0,
5 and 15min, rOPN stimulates phosphorylation of
Tyr861 by 5 and 15min of cell suspension (Figure 4A).
The slight increase of FAK phosphorylation at Tyr861
in BSA after 15min of cell suspension is likely due
to FN or VN in serum, since FN have been shown to
increase phosphorylation at Tyr861 of adherent cancer
cells [42].
Additionally, the inhibition of autophosphoryla-
tion of FAK at Tyr397 by FAK inhibitor 14 also
inhibited the phosphorylation of FAK at Tyr861
even in the presence of rOPN, indicating that
autophosphorylation of FAK at Tyr397 is required,
prior to OPN-induced phosphorylation of FAK at
Tyr861, Figure 4B. Since FAK inhibitor 14 also
inhibited the suppression of caspase-8 activity by
rOPN, Figure 3E, these findings indicate that attenu-
ation of anoikis by rOPN is mediated through FAK
phosphorylation at Tyr861.
OPN Suppression of Caspase-8 Activation Is Mediated
through FAK Phosphorylation at Tyr861
To further confirm that OPN suppression of
caspase-8 activity is mediated through the phosphor-
ylation of FAK at Tyr861, cells were transfected with
control vector or vectors expressing wild-type FAK or
mutant FAKs where Tyr861 is mutated to Phe861 (FAK-
Y861F) or Tyr925 is mutated to Phe925 (FAK-Y925F)
abolishing phosphorylation at these residues. Mutant
FAK-Y925Fwas included, because its phosphorylation
at 925 has been reported to occur in an adhesion-
independent manner [43]. Caspase-8 activities of
suspended JB6 cells expressing various forms of FAK
in the presence of rOPN or BSA were measured. Cells
over-expressing FAK had lower caspase-8 activity
relative to values for cells with the vector control,
and addition of OPN did not further decrease its
activity (Figure 4C). Unlike most cancer cells, the
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Figure 4. OPN stimulates FAK phosphorylation at Tyr861, which
mediates suppression of caspase-8 activity to enhance survival of
suspended JB6 cells. (A) Western blot and densitometric analyses of
FAK phosphorylation at Tyr861. Cells were suspended with rOPN (OPN)
or 1% BSA in growth media for 0, 5, or 15min on agar. Cell lysates
(1mg) were immunoprecipitated with antibody for total FAK and
probed with anti-FAK phospho-Tyr861 (P-Tyr861), followed by antibody
for total FAK, ﬁlm exposure times were 5 s. Lower panel is a histogram
of densitometric analyses fromWestern blot analyses, n¼ 3/treatment.
(B) Western blot analyses of FAK phosphorylation at Tyr861 of
suspended cells in serum containing medium treated with FAK
inhibitor 14 and OPN. Cell lysates (800mg) were immunoprecipitated
with anti-total FAK antibody and treated as above, ﬁlm exposure time is
10min (top panel) and 5–10 s (lower panel). (C) Caspase-8 activity
of suspended cells transfected wild-type FAK and mutant FAKs. Top
panel, cells were transfected with plasmids of vector only (C), wild-type
FAK (W), mutant FAK-Y861F (Y861F), or mutant FAK-Y925F (Y925F).
After 24 h of incubation, these cells were examined for the expression
of FAK and the mutant FAKs by Western blot analysis (20mg/lane).
Relative amounts of transfected mutant FAK to that of transfected
recombinant wild-type FAK are speciﬁed below the top ﬁlm. Lower
panel, in parallel dishes, the transfected cells were suspended with
1.4mg/ml of rOPN or 1%BSA for 1 h prior to assay of caspase-8 activity,
n¼ 3/treatment. Caspase-8 activity from cells transfected with vector
only and treated with 1% BSA was set to 1, and all the other caspase-8
activities were normalized to vector control. (D) Histogram of live cells
after 1 and 5 h of suspension followed by re-plating on tissue culture
dishes for 10 h. Adherent cells were trypsinized and counted by
hemocytometer, n¼ 3/treatment. Data are representative of two to
three independent experiments.
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preneoplastic JB6 cells normally express low levels of
FAK. Therefore, consistent with other studies on over-
expression of FAK [32,44,45], we expected JB6 cells to
gain resistance to anoikis and have lower caspase-8
activation.
Cells expressing excess mutant FAK-Y861F in BSA
showed increased caspase-8 activity relative to cells
expressing vector control or wild-type FAK
(Figure 4C). Further, the addition of rOPN showed
no inhibition of caspase-8 activity, because the
mutated site at 861 of FAK does not allow OPN-
induced phosphorylation at 861. Our data clearly
indicate that OPN phosphorylation of Tyr861 is
necessary to decrease caspase-8 activity and promote
cell survival.
In contrast to cells with mutant FAK-Y861F, cells
expressing mutated FAK-Y925F in BSA did not
significantly increase caspase-8 activity relative to
cells transfected with the vector control and treated
with BSA (P¼0.1). However, overexpression of
FAKY925F abrogated the ability of OPN to suppress
caspase-8 activity. This suggests that suppression of
caspase-8 activation by rOPNmay in part be regulated
through the phosphorylation of FAK at Tyr925.
Additional studies on whether OPN stimulated
phosphorylation of FAK at Tyr925 by Western blot
analyses were inconclusive due to lack of antibody
specificity. Thus far, our results support a function of
OPN in suppressing caspase-8 activity, which is, at
least in part, mediated through phosphorylation of
FAK at Tyr861.
Addition of OPN to Suspended JB6 Cells Results in Greater
Numbers of Cells Surviving When They Are Re-Plated Onto
Tissue Culture Dishes
The results above support the concept that OPN is
involved in delaying anoikis through activation of
FAK at Tyr861 and in suppressing caspase-8 activity. To
test the capacity of OPN for prolonging the survival of
these cells in suspension, we determined if suspended
JB6 cells incubated with OPN have an advantage over
non-treated cells in attaching and surviving when
they are re-plated on tissue culture dishes. This was
indeed the case, since after adding rOPN to suspended
cells for 1 or 5h, there weremore attached cells on the
plates relative those incubated with BSA only
(Figure 4D).
DISCUSSION
Our studies demonstrate that the mechanism by
which induced OPN facilitates tumorigenic transfor-
mation of preneoplastic epidermal-like JB6 cells is not
by stimulating cell proliferation, but rather by
suppressing apoptosis. Adherent JB6 cells treated
with soluble rOPN exhibit similar cell proliferation
assessed by (i) direct cell counting, (ii) analysis of the
number of cells at selected cell cycle stage (set by DNA
level), and (iii) cyclin D1 expression as cells treated
with control. This finding is consistent with our
previous observation that suppression of TPA-in-
duced OPN expression and secretion by stably trans-
fecting JB6 cells with antisense OPN does not
significantly attenuate JB6 cell proliferation com-
pared with JB6 cells transfected with vector
control [17].
Using the over-agar assay to mimic early time
points of soft-agar assay, soluble rOPN delays/sup-
presses anoikis of JB6 cells, as indicated by the
reduction in surface PS compared with control cells.
JB6 cells in suspension exhibit sequential activation
of caspases-8, -9, and -3, which peak at 1, 3, and 18h,
respectively; these findings suggest that caspase-8 is
the primary initiator caspase [46] to induce anoikis in
JB6 cells. A specific threshold concentration of
exogenous rOPN (1.4mg/ml) is required to signifi-
cantly suppress caspase-8 activation of suspended JB6
cells, while a higher concentration of rOPN shows no
additional suppression, suggesting that the effect of
OPN is receptor mediated. Indeed, suppression of
caspase-8 activation by OPN is likely mediated
through interaction with integrins and not the
CD44 receptors, because peptides with its RGD-cell
binding motif that bind integrins, but not its
DRYLKFRI-cell binding motif, like OPN, suppress
caspase-8 activity. Our attempt to determine which
integrins mediate OPN suppression of caspase-8
activity was not successful; this may be because our
assays were performed with soluble rOPN in sus-
pended JB6 cells as opposed OPN-coated plates for
adherent cells [22].
Liganded integrin receptor potentially signals
through the PI3 kinase pathway and/or the FAK
pathway to enhance cell survival. Our result using PI3
kinase inhibitor, wortmannin, indicates that the
observed suppression of caspase-8 activity by rOPN
is not mediated through PI3 kinase, but rather
through activation of FAK, requiring the autophos-
phorylation of FAK at Tyr397 followed by specific
phosphorylation at Tyr861 and possibly, at Tyr925. In
the presence of serum, rOPN stimulates the phos-
phorylation of FAK at Tyr861 and participates with
other matrix proteins (FN and VN) in the serum to
activate FAK autophosphorylation at Tyr397 of sus-
pended JB6 cells. FAK inhibitor 14, which inhibits
autophosphorylation of FAK at Tyr397, abrogates
rOPN-induced phosphorylation of FAK at Tyr861
and rOPN suppression of caspase-8 activity, indicat-
ing that autophosphorylation of FAK at Tyr379 is
required prior to phosphorylation of at Tyr861 by
rOPN to suppress caspase-8 activity. Transfection
assays with mutant FAK-Y861F further confirmed
the requirement of phosphorylation of FAK at Tyr861
by OPN to suppress caspase-8 activity, because the
removal of the phosphorylation site at Tyr861 abro-
gated the ability of OPN to inhibit caspase-8 activity.
There is also the possibility that suppression of
caspase-8 activity by OPN is mediated through the
phosphorylation of FAK at Tyr925, as cells transfected
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with mutant FAK-Y925F also did not exhibit a
reduction in caspase-8 activity in the presence of
rOPN. Our Western blot analysis of phosphorylated
FAK at Tyr925 byOPNwas inconclusive due to the lack
of antibody specificity. Our studies, collectively,
suggest that in prevention of anoikis of epidermal-
like pre-neoplastic JB6 cells, OPN can stimulate
autophosphorylation of FAK at Tyr397 (if in serum-
free media) and, followed by FAK phosphorylation at
861 and possibly, at 925 in suppressing caspase-8
activities to enhance cell survival. Analogous to our
findings with suspended pre-neoplastic JB6 cells, OPN
promotes the survival of adherent cancer cells over-
expressing OPN in hypoxia plus serum-starved con-
ditions, and that OPN’s effect is mediated through
activation of FAK at Tyr397 requiring its RGD
motif [47].
FAK consists of four distinct domains: the
N-terminal four-point-one, ezrin, radixin, moesin
(FERM) domain, a catalytic kinase domain, two
proline-rich domains, and a C-terminal focal adhe-
sion targeting (FAT) domain. The general consensus
of an inactive FAK is that the FERM domain interacts
with the kinase domain. Engagement of ligands
(matrix proteins or growth factors) with integrins or
growth factor receptors triggers autophosphoryla-
tion of FAK at Tyr397, resulting in a conformational
change allowing the docking of Src and subsequent
phosphorylation of the tyrosine residues in the
kinase domain to activate FAK [35,48]. The docking
of Src or its activation results not only in phosphor-
ylation of the catalytic kinase domain of FAK, but
also in phosphorylation of the residues, Tyr861 and
Tyr925 [33,49–51]. Whether Src mediates OPN
stimulation of phosphorylation of FAK at Tyr861
and/or at Tyr925 in preventing anoikis remains to be
determined.
The present study resolves the question regarding
the mechanism by which induced OPN facilitates
TPA-induced tumorigenic transformation or colony
formation of pre-neoplastic epidermal-like JB6 cells in
soft-agar [17], Figure 5. By using excess exogenous
OPN to mimic TPA-induced OPN expression, we
found that OPN, through its RGDmotif interacts with
integrins, resulting in phosphorylation of FAK at
Tyr861 to suppress caspase-8 activity and thereby,
delays anoikis. In the presence of TPA, it stimulates
suspended JB6 cell to secrete a 4-fold increase of OPN
over that of control cells. Secreted OPN acts as an
autocrine factor in promoting cell survival, and
facilitates cell transformation in soft-agar. Soft-agar
assays are performed in the presence of serum
containing both FN and VN. Furthermore, in the
presence of tumor promoter, TPA can also stimulate
FN synthesis, but TPA-treated JB6 cells show reduced
adhesion to FN andVNby 45% and 55%, respectively,
relative to control cells, while a marked increase
attachment to OPN (28–fold compared to control
cells) is observed [22]. Therefore, TPA-treated cells in
soft-agar likely have a greater preference for OPN
compared to FN and VN, supporting our previous
observation that down-regulation of OPN compro-
mises TPA-induced colony formation [17].
This study is significant as it has broad implication
for epithelial tissues that normally do not express
OPN, butwhen induced by external or internal factors
may facilitate the survival of initiated cells and
allowing them to remain dormant prior to trans-
forming into benign and/ormalignant cells. Evidence
from our in two-stage chemically-induced skin
carcinogenesis study also supports the presence of
inducedOPN in protecting basal normal and initiated
keratinocytes [1]. In adult skin, OPN is minimally
expressed like that of epidermal JB6 cells. Upon
Figure 5. Hypothetical model of OPN facilitating tumorigenic
transformation of JB6 Cl41.5a cells by preventing anoikis. JB6
Cl41.5a (JB6) is a preneoplastic epidermal-like cell line used as an in
vitro model for late-stage tumor promotion. TPA stimulates colony
formation or tumorigenic transformation of JB6 cells and concomitantly
induces the synthesis and secretion of OPN [18,19]. We postulate that
TPA induces a fourfold increase of OPN secreted by cells (Table 1)
embedded in soft-agar and that OPN resides close to the cell surfaces of
the cells. Soft agar assays are performed in the presence serum
containing both FN and VN and furthermore, TPA may also induce FN
secretion [17], thus JB6 cells embedded in soft-agar can also interact
with these matrix proteins. However, TPA-treated JB6 cells show
reduced adhesion to FN and VN by 45% and 55%, respectively, relative
to control cells, while a marked increase attachment to OPN (28-fold
compared to control cells) is observed [22]. Therefore, TPA-treated cells
in soft-agar likely have a greater preference for OPN compared to FN
and VN, supporting our previous observation that down-regulation of
OPN compromises TPA-induced colony formation [17]. Base on over-
agar assay, by use of exogenous OPN to mimic TPA-induced OPN
expression, we conclude that OPN, through its RGD motif, speciﬁcally
phosphorylates FAK at Tyr861 to suppress caspase-8 activity and
thereby, delays anoikis facilitating tumorigenic transformation of JB6
cells. OPNRGD, osteopontin synthesized by JB6 cells; FNRGD, ﬁbronectin
synthesized by JB6 cells and from serum; VNRGD, vitronectin in serum;
FAK, focal adhesion kinase; 397, phosphorylation of FAK at Tyr397; 861,
phosphorylation of FAK at Tyr861.
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treatment with the carcinogen, 7, 12-dimethylbenz
(a)anthracene (DMBA) and/or TPA, OPN is markedly
expressed in the epidermis by fourfold and over
20-fold, respectively. Thus, we postulate that in a
recurrent stressed environment, OPN secreted into
the epidermal microenvironment, not only protects
normal keratinocytes, but also enables carcinogen-
induced, initiated keratinocytes to survive for an
extended period of time, resulting in increased
likelihood of developing more papillomae than
would occur in the absence of secreted OPN.
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